Panitumumab in colorectal cancer

References

• Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res.46, 4726–4731, (1986).
   PubMed Web of Science ®Google Scholar
• Yasui W, Sumiyoshi H, Hata J et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res.48(1), 137–141 (1988).
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol.2(2), 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• Yokoi K, Thaker PH, Yazici S et al. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res.65(9), 3716–3725 (2005).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Rougier P, Raoul JL, Van Laethem JL et al. Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer. J. Clin. Oncol.22, 3513 (2004).
   Google Scholar
• Tabernero JM, Van Cutsem J, Sastre J et al. An international Phase II study of cetuximab in combination with oxaliplatin/5-FU/folinic acid (FOLFOX-4) in the first line treatment of patients with metastatic colorectal cancer expressing EGFR. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
   Google Scholar
• Erbitux®, Package Insert. ImClone Systems Inc., NJ, USA.
   Google Scholar
• Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol.29(1 Suppl. 4), 47–50 (2002).
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan J, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res.59, 1236–1243 (1999).
   PubMed Web of Science ®Google Scholar
• Foon K, Yang XD, Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys.58, 984–990 (2004).
   PubMed Web of Science ®Google Scholar
• Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. DOI 10.1111/j.1349-7006.2007.00510 (2007) (Epub ahead of print).
   Google Scholar
• Crawford J, Sandler AB, Hammond LA et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non small cell lung cancer. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
   Google Scholar
• Weiner L. Updated results from a dose and schedule study of panitumumab (ABX–EGF) monotherapy, in patients with advanced solid malignancies. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar
• Rowinsky EK, Schwartz GH, Gollub JA et al. Safety, pharmacokinetics, and activity of ABX–EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol.22, 3003–3015 (2004).
   PubMed Web of Science ®Google Scholar
• Malik I, Hecht JR, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar
• Berlin J, Neubauer M, Swanson P et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
   Google Scholar
• Hecht JR, Mitchell E, Baranda J et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
   Google Scholar
• Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25, 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Saltz L, Lenz H, Kindler HL et al. Interim report of randomized Phase II trial of cetuximab/bevacizumab/irinotecan vs cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Hollywood, FL, USA, 27–29 January 2005 (Abstract 169b).
   Google Scholar
• Cohen RB, Falcey JW, Paulter VJ et al. Safety profile of the monoclonal antibody C225 in the treatment of EGFr positive tumors. Proceedings of the 36th Annual meeting of the American Society of Clinical Oncology. New Orleans, LA, USA, 19–23 May 2000 (Abstract 1862).
   Google Scholar
• Hecht JR, Peeters M, Van Cutsem E, Berlin J, Visonneau S. Safety and tolerability of panitumumab, a fully human monoclonal antibody (Mab), in patients (Pts) with metastatic colorectal cancer (mCRC). Ann. Oncol.17(Suppl. 9), 361 (2006).
   PubMed Web of Science ®Google Scholar
• Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology20(11), 1373–1382 (2006).
   PubMed Web of Science ®Google Scholar
• Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl Cancer Inst.97(16), 1221–1224 (2005).
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23, 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Starling N, Cunningham D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr. Opin. Oncol.16(4), 385–390 (2004).
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J. Clin. Oncol.22(23), 4772–4778 (2004).
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Ychou M et al. KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with cetuximab. Proceedings of the American Association for Cancer Research Annual Meeting. Los Angeles, CA, USA, 14–18 April 2007.
   Google Scholar
• Ford S, Garrett CR, Clark EA et al. Expression of epiregulin and amphiregulin and K-RAS mutation status predicit disease control in metastatic colorectal cancer patients treated with cetuximab. Proceedings of the American Association for Cancer Research Annual Meeting. Los Angeles, CA, USA, 14–18 April 2007.
   Google Scholar
• Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin. Lung Cancer.8(Suppl. 1), S7–S14 (2006).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Humblet Y, Gelderblom H et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): PK and efficacy data of a randomized study. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19–21 January 2007.
   Google Scholar